Streetbeat News

Analyst Ratings

GNFT

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Genfit (NASDAQ:GNFT) and raises the price target from $9 to $11.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:03 pm

THTX

Canaccord Genuity analyst Edward Nash assumes Theratechnologies (NASDAQ:THTX) with a Hold rating and announces a price target of $2.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:02 pm

BIIB

IONS

NVS

Biogen Inc has announced new data on its drug Spinraza, showing improved motor function in infants and toddlers with spinal muscular atrophy (SMA) who had previously been treated with Novartis AG's gene therapy, Zolgensma. The data comes from an ongoing two-year, phase 4 open-label study. Analysts from William Blair suggest that the results indicate the added benefit of Spinraza treatment and predict that it will remain a significant contributor to Biogen's revenues, as well as those of its development partner, Ionis Pharmaceuticals Inc.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 12:36 pm

VRTX

Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $305 to $340.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:34 pm

SPLK

Morgan Stanley analyst Keith Weiss has reiterated an Equal-Weight rating on Splunk (NASDAQ:SPLK) and maintained a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:34 pm

SGTX

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $7 to $21.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:33 pm

NKE

Morgan Stanley analyst Alex Kurtz has maintained an Overweight rating on Nike (NYSE:NKE) but lowered the price target from $130 to $127.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:31 pm

IJR

J

RIG

V

CNBC's 'Halftime Report Final Trades' featured recommendations from various analysts. Stephen Weiss of Short Hills Capital Partners recommended Jacobs Solutions Inc. (NYSE:J) citing its recent Engineering Partnering Agreement with Fortescue Future Industries. Bryn Talkington of Requisite Capital Management recommended Visa Inc. (NYSE:V), highlighting its recent acquisition of Pismo and the upcoming earnings season for financial stocks. Jim Lebenthal of Cerity Partners recommended Transocean Ltd. (NYSE:RIG) following its $184-million award for semisubmersible services. Liz Young of BNY Mellon Investment Management recommended iShares Core S&P Small-Cap ETF (NYSE:IJR).

Portfolio Pulse from Lisa Levin

July 03, 2023 | 12:30 pm

PAYX

Morgan Stanley analyst James Faucette has reiterated an Equal-Weight rating on Paychex (NASDAQ:PAYX) and maintained a $125 price target.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:28 pm

ACMR

BTAI

CPA

CUBE

ETNB

ETON

IPG

MKC

NKE

PAYX

WFC

Several analyst forecasts were released on Monday, with price target changes for ACM Research, 89bio, The Interpublic Group of Companies, McCormick & Company, BioXcel Therapeutics, Wells Fargo & Company, Eton Pharmaceuticals, Paychex, CubeSmart, Copa Holdings, and International Flavors & Fragrances. Most of the companies saw their price targets increased, with a few exceptions.

Portfolio Pulse from Lisa Levin

July 03, 2023 | 12:24 pm